SERAXIS Inc., a rapidly growing regenerative medicine company today announced the publication of important trial considerations for SR-01, its pluripotent stem cell-derived islet therapy for insulin-dependent diabetes.
{iframe}https://www.prnewswire.com/news-releases/seraxis-inc-publishes-clinical-trial-considerations-for-a-type-1-diabetes-stem-cell-derived-therapy-300747501.html{/iframe}